Last reviewed · How we verify

NCT07184814: CAPTAIN

Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement

Recruiting now Last updated 22 September 2025
What this trial tests

trial in Takayasu Arteritis With Pulmonary Artery Involvement in 150 participants. Currently enrolling.

Timeline
1 January 2016
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorChina-Japan Friendship Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment150
Start date1 January 2016
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across China

Conditions studied

Sponsor

China-Japan Friendship Hospital

Who can join

18 and older, any sex, with Takayasu Arteritis With Pulmonary Artery Involvement or Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Pulmonary hypertension in Takayasu arteritis with pulmonary artery involvement: risk factors and impact on mortality.
    Zheng S, Li Y, Liu Z, Chen Y, et al · · 2026 · PMID 41922023 · DOI 10.1136/bmjresp-2025-003854

Verify or expand the search:

Other recruiting trials for Takayasu Arteritis With Pulmonary Artery Involvement

Currently open trials in the same condition.

Other China-Japan Friendship Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07184814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing